Jill Gilmour

List of Publications by Year
in descending order

52	1,311	448610 19	425179 34
papers	citations	h-index	g-index

54	54	54	2602
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cohort Profile: IAVIâ€™s HIV epidemiology and early infection cohort studies in Africa to support vaccine discovery. International Journal of Epidemiology, 2021, 50, 29-30.	0.9	11
2	A Stronger Innate Immune Response During Hyperacute Human Immunodeficiency Virus Type 1 (HIV-1) Infection Is Associated With Acute Retroviral Syndrome. Clinical Infectious Diseases, 2021, 73, 832-841.	2.9	5
3	Utilizing Computational Machine Learning Tools to Understand Immunogenic Breadth in the Context of a CD8 T-Cell Mediated HIV Response. Frontiers in Immunology, 2021, 12, 609884.	2.2	5
4	Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials. African Journal of Laboratory Medicine, 2021, 10, 1056.	0.2	5
5	A Novel Sample Selection Approach to Aid the Identification of Factors That Correlate With the Control of HIV-1 Infection. Frontiers in Immunology, 2021, 12, 634832.	2.2	4
6	Comprehensive epitope mapping using polyclonally expanded human CD8 T cells and a two-step ELISpot assay for testing large peptide libraries. Journal of Immunological Methods, 2021, 491, 112970.	0.6	8
7	Subtype-specific differences in Gag-protease replication capacity of HIV-1 isolates from East and West Africa. Retrovirology, 2021, 18, 11.	0.9	2
8	Breadth of CD8 T-cell mediated inhibition of replication of diverse HIV-1 transmitted-founder isolates correlates with the breadth of recognition within a comprehensive HIV-1 Gag, Nef, Env and Pol potential T-cell epitope (PTE) peptide set. PLoS ONE, 2021, 16, e0260118.	1.1	6
9	HIV-1 variants are archived throughout infection and persist in the reservoir. PLoS Pathogens, 2020, 16, e1008378.	2.1	37
10	Evaluation of antiviral T cell responses and TSCM cells in volunteers enrolled in a phase I HIV-1 subtype C prophylactic vaccine trial in India. PLoS ONE, 2020, 15, e0229461.	1.1	7
11	Identifying the immune interactions underlying HLA class I disease associations. ELife, 2020, 9, .	2.8	17
12	Title is missing!. , 2020, 15, e0229461.		0
13	Title is missing!. , 2020, 15, e0229461.		0
14	Title is missing!. , 2020, 15, e0229461.		0
15	Title is missing!. , 2020, 15, e0229461.		0
16	Title is missing!. , 2020, 15, e0229461.		0
17	Title is missing!. , 2020, 15, e0229461.		0
18	Title is missing!. , 2020, 16, e1008853.		0

#	Article	IF	Citations
19	Title is missing!. , 2020, 16, e1008853.		0
20	Title is missing!. , 2020, 16, e1008853.		0
21	Title is missing!. , 2020, 16, e1008853.		0
22	Reduced frequency of HIV superinfection in a high-risk cohort in Zambia. Virology, 2019, 535, 11-19.	1.1	1
23	Protective HLA alleles are associated with reduced LPS levels in acute HIV infection with implications for immune activation and pathogenesis. PLoS Pathogens, 2019, 15, e1007981.	2.1	7
24	Induction and maintenance of bi-functional (IFN-Î³ + IL-2+ and IL-2+ TNF-Î±+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India. PLoS ONE, 2019, 14, e0213911.	1.1	6
25	Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India. PLoS ONE, 2018, 13, e0203037.	1.1	11
26	Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. Journal of Virology, 2018, 92, .	1.5	3
27	Cryopreservation-related loss of antigen-specific IFNÎ³ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. Vaccine, 2017, 35, 1898-1906.	1.7	40
28	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. Journal of Infectious Diseases, 2017, 216, 1063-1069.	1.9	20
29	First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virusâ€“Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. Journal of Infectious Diseases, 2017, 215, 95-104.	1.9	38
30	A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. Frontiers in Immunology, 2017, 8, 149.	2.2	35
31	A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Frontiers in Immunology, 2017, 8, 595.	2.2	20
32	Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination. Frontiers in Immunology, 2017, 8, 1883.	2.2	13
33	Dynamics and Correlates of CD8 T-Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2016, 90, 10423-10430.	1.5	2
34	Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16061.	1.8	39
35	Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention. Annals of Internal Medicine, 2016, 164, 313.	2.0	70
36	Control of HIV-1 replication in vitro by vaccine-induced human CD8+ T cells through conserved subdominant Pol epitopes. Vaccine, 2016, 34, 1215-1224.	1.7	35

#	Article	IF	Citations
37	Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort. PLoS Pathogens, 2016, 12, e1005369.	2.1	241
38	CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data. Frontiers in Microbiology, 2015, 6, 670.	1.5	12
39	A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. PLoS ONE, 2015, 10, e0125954.	1.1	31
40	A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults. PLoS ONE, 2015, 10, e0134287.	1.1	39
41	Transmitted Virus Fitness and Host T Cell Responses Collectively Define Divergent Infection Outcomes in Two HIV-1 Recipients. PLoS Pathogens, 2015, 11, e1004565.	2.1	44
42	Canine distemper virus neutralization activity is low in human serum and it is sensitive to an amino acid substitution in the hemagglutinin protein. Virology, 2015, 482, 218-224.	1.1	11
43	Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4 ⁺ T cells, and disease progression. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1480-9.	3.3	87
44	Creating an African HIV Clinical Research and Prevention Trials Network: HIV Prevalence, Incidence and Transmission. PLoS ONE, 2015, 10, e0116100.	1.1	43
45	High Transmitter CD4+ T-Cell Count Shortly after the Time of Transmission in a Study of African Serodiscordant Couples. PLoS ONE, 2015, 10, e0134438.	1.1	2
46	Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS ONE, 2014, 9, e90378.	1.1	13
47	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Molecular Therapy, 2014, 22, 464-475.	3.7	188
48	Dynamics of viremia in primary HIV-1 infection in Africans: Insights from analyses of host and viral correlates. Virology, 2014, 449, 254-262.	1.1	13
49	Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. Journal of Immunological Methods, 2014, 409, 161-173.	0.6	28
50	Acceptability and Feasibility of Repeated Mucosal Specimen Collection in Clinical Trial Participants in Kenya. PLoS ONE, 2014, 9, e110228.	1.1	8
51	Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories. PLoS ONE, 2010, 5, e14330.	1.1	47
52	Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents. Vaccine Journal, 2009, 16, 147-155.	3.2	57